These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38531834)

  • 1. A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements.
    Bonifacio M; Scaffidi L; Miggiano MC; Facchinelli D; Tosoni L; Pezone S; Griguolo D; Ciotti G; Danini M; Bernardelli A; Bresciani R; Cavraro M; Crosera L; De March E; Dell'Eva M; Dorotea L; Frison L; Furlani L; Gianesello I; Lovato E; Marchetti E; Morelli G; Mullai R; Pizzano U; Zoletto S; Fanin R; Krampera M; Trentin L; Calistri E; Carli G; Binotto G; Tiribelli M
    Blood Cancer J; 2024 Mar; 14(1):53. PubMed ID: 38531834
    [No Abstract]   [Full Text] [Related]  

  • 2. Deep molecular responses for treatment-free remission in chronic myeloid leukemia.
    Dulucq S; Mahon FX
    Cancer Med; 2016 Sep; 5(9):2398-411. PubMed ID: 27367039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
    Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia.
    Goldberg SL; Savona M; Mauro MJ
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):98-105. PubMed ID: 29274688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Campiotti L; Suter MB; Dentali F
    Cancer; 2021 Mar; 127(6):976. PubMed ID: 33095907
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E; Torregrosa-Diaz J; Leleu X; Guilhot F; Chomel JC
    Cancer; 2021 Mar; 127(6):976-978. PubMed ID: 33095912
    [No Abstract]   [Full Text] [Related]  

  • 7. [Chronic myeloid leukemia: aiming for treatment free remission].
    Kimura S
    Rinsho Ketsueki; 2021; 62(6):572-581. PubMed ID: 34219083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence.
    Baccarani M
    Leukemia; 2017 Apr; 31(4):1015-1016. PubMed ID: 28093565
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia.
    Tiribelli M; Toffoletti E; Di Giusto S; Fanin R; Damiani D
    Eur J Haematol; 2023 Mar; 110(3):330-331. PubMed ID: 36458956
    [No Abstract]   [Full Text] [Related]  

  • 10. Nilotinib in the treatment of chronic myeloid leukemia.
    Sacha T; Saglio G
    Future Oncol; 2019 Mar; 15(9):953-965. PubMed ID: 30547682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.
    Breccia M; Foà R
    Curr Oncol Rep; 2018 Mar; 20(3):23. PubMed ID: 29511948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ph-positive acute lymphoblastic leukemia after long-term remission of Ph-positive acute myeloid leukemia.
    Nishida H; Yoshimizu N; Ueno H; Fujita A; Kato T; Park JW; Yano T; Tobinai K; Ikeda Y
    Leuk Res; 2007 Mar; 31(3):417-8. PubMed ID: 16730062
    [No Abstract]   [Full Text] [Related]  

  • 13. The (near) miracle of therapy in chronic myeloid leukaemia.
    Radich JP
    Br J Haematol; 2023 Sep; 202(5):919-921. PubMed ID: 37495373
    [No Abstract]   [Full Text] [Related]  

  • 14. Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice.
    Almeida A; Pierdomenico F; Guerrero BP; Saraiva F; Montalvão A; Coutinho J; Mariz M; Melo T; Santos MJ; Pereira A; Cerveira N
    Acta Med Port; 2019 Aug; 32(7-8):550-557. PubMed ID: 31445538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment discontinuation in chronic myeloid leukemia: When, how, and why?
    Haddad FG; Short NJ
    Am J Hematol; 2023 Nov; 98(11):1670-1672. PubMed ID: 37753704
    [No Abstract]   [Full Text] [Related]  

  • 16. On the road to treatment-free remission in chronic myeloid leukemia: what about 'the others'?
    Stagno F; Breccia M; Di Raimondo F
    Expert Rev Anticancer Ther; 2020 Dec; 20(12):1075-1081. PubMed ID: 32985290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching drugs midstream for patients with chronic myeloid leukemia.
    DeAngelo DJ
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):466-8. PubMed ID: 25322328
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of acute leukemias and chronic myeloid leukemias].
    Devergie A
    Soins; 2008 Mar; (723):44-5. PubMed ID: 18380312
    [No Abstract]   [Full Text] [Related]  

  • 19. E14a2
    Claudiani S; Apperley JF; Gale RP; Clark R; Szydlo R; Deplano S; Palanicawandar R; Khorashad J; Foroni L; Milojkovic D
    Haematologica; 2017 Aug; 102(8):e297-e299. PubMed ID: 28495914
    [No Abstract]   [Full Text] [Related]  

  • 20. Goals for chronic myeloid leukemia TK inhibitor treatment: how little disease is too much?
    Mauro MJ
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):234-9. PubMed ID: 25696860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.